Advertisement

Index by author

September 01, 1993; Volume 21,Issue 5

A

  1. Abbott, F S

    1. Identification of carbamoylated thiol conjugates as metabolites of the antineoplastic 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, in rats and humans.
      A G Borel and F S Abbott
      Drug Metabolism and Disposition September 1993, 21 (5) 889-901;

  2. Abdel-Rahman, M S

    1. Metabolism of benzophenone-3 in rats.
      C S Okereke, A M Kadry, M S Abdel-Rahman, R A Davis and M A Friedman
      Drug Metabolism and Disposition September 1993, 21 (5) 788-791;

  3. Abramson, F

    1. Drug metabolism studies using "intrinsic" and "extrinsic" labels. A demonstration using 15N vs. Cl in midazolam.
      H Song and F Abramson
      Drug Metabolism and Disposition September 1993, 21 (5) 868-873;

  4. Albrecht, E

    1. Disposition of the 3H-labeled gonadotropin-releasing hormone analog buserelin in rats.
      H Berger, J Sandow, N Heinrich, E Albrecht, U Kertscher and J Oehlke
      Drug Metabolism and Disposition September 1993, 21 (5) 818-822;

  5. Andrew, P D

    1. Disposition of sumatriptan in laboratory animals and humans.
      C M Dixon, D A Saynor, P D Andrew, J Oxford, A Bradbury and M H Tarbit
      Drug Metabolism and Disposition September 1993, 21 (5) 761-769;

B

  1. Bandyopadhyay, A M

    1. Effect of nutritional obesity on the induction of CYP2B enzymes following phenobarbital treatment.
      P N Zannikos, A M Bandyopadhyay, L W Robertson and R A Blouin
      Drug Metabolism and Disposition September 1993, 21 (5) 782-787;

  2. Batt, A M

    1. Identification of cytochrome P-450 isozymes involved in the hydroxylation of dantrolene by rat liver microsomes.
      Z Jayyosi, J Villoutreix, J M Ziegler, A M Batt, F De Maack, G Siest and P E Thomas
      Drug Metabolism and Disposition September 1993, 21 (5) 939-945;

  3. Berger, H

    1. Disposition of the 3H-labeled gonadotropin-releasing hormone analog buserelin in rats.
      H Berger, J Sandow, N Heinrich, E Albrecht, U Kertscher and J Oehlke
      Drug Metabolism and Disposition September 1993, 21 (5) 818-822;

  4. Bernadou, J

    1. Model systems for oxidative drug metabolism studies. Catalytic behavior of water-soluble metalloporphyrins depends on both the intrinsic robustness of the catalyst and the nature of substrates.
      M Vidal, M Bonnafous, S Defrance, P Loiseau, J Bernadou and B Meunier
      Drug Metabolism and Disposition September 1993, 21 (5) 811-817;

  5. Bjorge, S M

    1. Bioactivation and irreversible binding of the cognition activator tacrine using human and rat liver microsomal preparations. Species difference.
      T F Woolf, W F Pool, S M Bjorge, T Chang, O P Goel, C F Purchase, M C Schroeder, K L Kunze and W F Trager
      Drug Metabolism and Disposition September 1993, 21 (5) 874-882;

  6. Blanz, J

    1. Detection and identification of human urinary metabolites of biantrazole (CI-941).
      J Blanz, U Renner, K Schmeer, G Ehninger and K P Zeller
      Drug Metabolism and Disposition September 1993, 21 (5) 955-961;

  7. Blouin, R A

    1. Effect of nutritional obesity on the induction of CYP2B enzymes following phenobarbital treatment.
      P N Zannikos, A M Bandyopadhyay, L W Robertson and R A Blouin
      Drug Metabolism and Disposition September 1993, 21 (5) 782-787;

  8. Bonnafous, M

    1. Model systems for oxidative drug metabolism studies. Catalytic behavior of water-soluble metalloporphyrins depends on both the intrinsic robustness of the catalyst and the nature of substrates.
      M Vidal, M Bonnafous, S Defrance, P Loiseau, J Bernadou and B Meunier
      Drug Metabolism and Disposition September 1993, 21 (5) 811-817;

  9. Bopp, B A

    1. Differences in the stereoselective pharmacokinetics of pazinaclone (DN-2327), a new anxiolytic, and its active metabolite after intravenous and oral single doses to dogs.
      Z Hussein, D J Mulford, B A Bopp and G R Granneman
      Drug Metabolism and Disposition September 1993, 21 (5) 805-810;

  10. Borel, A G

    1. Identification of carbamoylated thiol conjugates as metabolites of the antineoplastic 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, in rats and humans.
      A G Borel and F S Abbott
      Drug Metabolism and Disposition September 1993, 21 (5) 889-901;

  11. Boudinot, F D

    1. Pharmacokinetics and metabolism of 3'-azido-2',3'-dideoxy-5-methylcytidine in rhesus monkeys.
      F D Boudinot, R F Schinazi, K J Doshi, H M McClure and C K Chu
      Drug Metabolism and Disposition September 1993, 21 (5) 855-860;

  12. Bradbury, A

    1. Disposition of sumatriptan in laboratory animals and humans.
      C M Dixon, D A Saynor, P D Andrew, J Oxford, A Bradbury and M H Tarbit
      Drug Metabolism and Disposition September 1993, 21 (5) 761-769;

  13. Burka, L T

    1. Metabolism and elimination of oxazepam in B6C3F1 and Swiss-Webster mice.
      R J Griffin and L T Burka
      Drug Metabolism and Disposition September 1993, 21 (5) 918-926;

C

  1. Cano, J P

    1. Effect of anticancer drugs on the glucuronidation of 3'-azido-3'-deoxythymidine in human liver microsomes.
      J F Rajaonarison, B Lacarelle, J Catalin, A Durand and J P Cano
      Drug Metabolism and Disposition September 1993, 21 (5) 823-829;

  2. Cashman, J R

    1. Comparison of human and rhesus monkey in vitro phase I and phase II hepatic drug metabolism activities.
      J C Stevens, L A Shipley, J R Cashman, M Vandenbranden and S A Wrighton
      Drug Metabolism and Disposition September 1993, 21 (5) 753-760;

  3. Catalin, J

    1. Effect of anticancer drugs on the glucuronidation of 3'-azido-3'-deoxythymidine in human liver microsomes.
      J F Rajaonarison, B Lacarelle, J Catalin, A Durand and J P Cano
      Drug Metabolism and Disposition September 1993, 21 (5) 823-829;

  4. Chang, T

    1. Bioactivation and irreversible binding of the cognition activator tacrine using human and rat liver microsomal preparations. Species difference.
      T F Woolf, W F Pool, S M Bjorge, T Chang, O P Goel, C F Purchase, M C Schroeder, K L Kunze and W F Trager
      Drug Metabolism and Disposition September 1993, 21 (5) 874-882;

  5. Chauret, N

    1. Characterization of verlukast metabolites arising from an epoxide intermediate produced with hepatic microsomes from beta-naphthoflavone-treated rodents (P-4501A1).
      D A Nicoll-Griffith, N Chauret, J A Yergey, L A Trimble, L Favreau, R Zamboni, S J Grossman, J Drey and E Herold
      Drug Metabolism and Disposition September 1993, 21 (5) 861-867;

  6. Chen, I W

    1. Uptake of alendronate by bone tissue in hypocalcemic and hypercalcemic rats.
      J H Lin, I W Chen and F A Deluna
      Drug Metabolism and Disposition September 1993, 21 (5) 800-804;

  7. Chiu, S H

    1. N-glucuronidation reactions. I. Tetrazole N-glucuronidation of selected angiotensin II receptor antagonists in hepatic microsomes from rats, dogs, monkeys, and humans.
      S E Huskey, R R Miller and S H Chiu
      Drug Metabolism and Disposition September 1993, 21 (5) 792-799;

  8. Chou, C H

    1. Relationship between lipophilicity and hepatic dispersion and distribution for a homologous series of barbiturates in the isolated perfused in situ rat liver.
      C H Chou, A M Evans, G Fornasini and M Rowland
      Drug Metabolism and Disposition September 1993, 21 (5) 933-938;

  9. Chu, C K

    1. Pharmacokinetics and metabolism of 3'-azido-2',3'-dideoxy-5-methylcytidine in rhesus monkeys.
      F D Boudinot, R F Schinazi, K J Doshi, H M McClure and C K Chu
      Drug Metabolism and Disposition September 1993, 21 (5) 855-860;

  10. Chung, S J

    1. Nitrite ion is not an active intermediate in the vascular metabolism of organic nitrates and organic nitrites to nitric oxide.
      E A Kowaluk, S J Chung and H L Fung
      Drug Metabolism and Disposition September 1993, 21 (5) 967-969;

  11. Cretton, E M

    1. Reduction of 3'-azido-2',3'-dideoxynucleosides to their 3'-amino metabolite is mediated by cytochrome P-450 and NADPH-cytochrome P-450 reductase in rat liver microsomes.
      E M Cretton and J P Sommadossi
      Drug Metabolism and Disposition September 1993, 21 (5) 946-950;

  12. Criscuoli, M

    1. Pharmacokinetics and pharmacodynamics of idrapril in rats, dogs, and humans.
      M Criscuoli, A Lippi, G Mengozzi, G Sardelli, A Subissi and A Giachetti
      Drug Metabolism and Disposition September 1993, 21 (5) 835-840;

D

  1. Davis, R A

    1. Metabolism of benzophenone-3 in rats.
      C S Okereke, A M Kadry, M S Abdel-Rahman, R A Davis and M A Friedman
      Drug Metabolism and Disposition September 1993, 21 (5) 788-791;

  2. Dedinas, J

    1. A strategy for characterization of polyethylene glycol-derivatized proteins. A mass spectrometric analysis of the attachment sites in polyethylene glycol-derivatized superoxide dismutase.
      M M Vestling, C M Murphy, D A Keller, C Fenselau, J Dedinas, D L Ladd and M A Olsen
      Drug Metabolism and Disposition September 1993, 21 (5) 911-917;

  3. Defrance, S

    1. Model systems for oxidative drug metabolism studies. Catalytic behavior of water-soluble metalloporphyrins depends on both the intrinsic robustness of the catalyst and the nature of substrates.
      M Vidal, M Bonnafous, S Defrance, P Loiseau, J Bernadou and B Meunier
      Drug Metabolism and Disposition September 1993, 21 (5) 811-817;

  4. Deluna, F A

    1. Uptake of alendronate by bone tissue in hypocalcemic and hypercalcemic rats.
      J H Lin, I W Chen and F A Deluna
      Drug Metabolism and Disposition September 1993, 21 (5) 800-804;

  5. De Maack, F

    1. Identification of cytochrome P-450 isozymes involved in the hydroxylation of dantrolene by rat liver microsomes.
      Z Jayyosi, J Villoutreix, J M Ziegler, A M Batt, F De Maack, G Siest and P E Thomas
      Drug Metabolism and Disposition September 1993, 21 (5) 939-945;

  6. Dixon, C M

    1. Disposition of sumatriptan in laboratory animals and humans.
      C M Dixon, D A Saynor, P D Andrew, J Oxford, A Bradbury and M H Tarbit
      Drug Metabolism and Disposition September 1993, 21 (5) 761-769;

  7. Doshi, K J

    1. Pharmacokinetics and metabolism of 3'-azido-2',3'-dideoxy-5-methylcytidine in rhesus monkeys.
      F D Boudinot, R F Schinazi, K J Doshi, H M McClure and C K Chu
      Drug Metabolism and Disposition September 1993, 21 (5) 855-860;

  8. Drey, J

    1. Characterization of verlukast metabolites arising from an epoxide intermediate produced with hepatic microsomes from beta-naphthoflavone-treated rodents (P-4501A1).
      D A Nicoll-Griffith, N Chauret, J A Yergey, L A Trimble, L Favreau, R Zamboni, S J Grossman, J Drey and E Herold
      Drug Metabolism and Disposition September 1993, 21 (5) 861-867;

  9. Durand, A

    1. Effect of anticancer drugs on the glucuronidation of 3'-azido-3'-deoxythymidine in human liver microsomes.
      J F Rajaonarison, B Lacarelle, J Catalin, A Durand and J P Cano
      Drug Metabolism and Disposition September 1993, 21 (5) 823-829;

E

  1. Ehninger, G

    1. Detection and identification of human urinary metabolites of biantrazole (CI-941).
      J Blanz, U Renner, K Schmeer, G Ehninger and K P Zeller
      Drug Metabolism and Disposition September 1993, 21 (5) 955-961;

  2. Elfarra, A A

    1. Targeting of 6-mercaptopurine to the kidneys. Metabolism and kidney-selectivity of S-(6-purinyl)-L-cysteine analogs in rats.
      A A Elfarra and I Y Hwang
      Drug Metabolism and Disposition September 1993, 21 (5) 841-845;

  3. Evans, A M

    1. Relationship between lipophilicity and hepatic dispersion and distribution for a homologous series of barbiturates in the isolated perfused in situ rat liver.
      C H Chou, A M Evans, G Fornasini and M Rowland
      Drug Metabolism and Disposition September 1993, 21 (5) 933-938;

F

  1. Faudskar, A L

    1. Glucuronidation as a transient intermediate metabolic step in the elimination of (-)-carbovir. Identification of (-)-carbovir-5'-O-glucuronide in rat bile.
      C L Zimmerman, K R Iyer, A L Faudskar and R P Remmel
      Drug Metabolism and Disposition September 1993, 21 (5) 902-910;

  2. Favreau, L

    1. Characterization of verlukast metabolites arising from an epoxide intermediate produced with hepatic microsomes from beta-naphthoflavone-treated rodents (P-4501A1).
      D A Nicoll-Griffith, N Chauret, J A Yergey, L A Trimble, L Favreau, R Zamboni, S J Grossman, J Drey and E Herold
      Drug Metabolism and Disposition September 1993, 21 (5) 861-867;

  3. Fenselau, C

    1. A strategy for characterization of polyethylene glycol-derivatized proteins. A mass spectrometric analysis of the attachment sites in polyethylene glycol-derivatized superoxide dismutase.
      M M Vestling, C M Murphy, D A Keller, C Fenselau, J Dedinas, D L Ladd and M A Olsen
      Drug Metabolism and Disposition September 1993, 21 (5) 911-917;

  4. Forkert, P G

    1. Temporal effects of 1,1-dichloroethylene on nonprotein sulfhydryl content in murine lung and liver.
      P G Forkert and M Moussa
      Drug Metabolism and Disposition September 1993, 21 (5) 770-776;

  5. Fornasini, G

    1. Relationship between lipophilicity and hepatic dispersion and distribution for a homologous series of barbiturates in the isolated perfused in situ rat liver.
      C H Chou, A M Evans, G Fornasini and M Rowland
      Drug Metabolism and Disposition September 1993, 21 (5) 933-938;

  6. Franklin, L K

    1. Disposition of tirilazad (U74006F), a 21-aminosteroid, in the plasma, heart, brain, and liver of the rat.
      S C Laizure, L K Franklin, D G Kaiser, C L Williams, R C Stevens, P L Sanders and M Miller
      Drug Metabolism and Disposition September 1993, 21 (5) 951-954;

  7. Friedman, M A

    1. Metabolism of benzophenone-3 in rats.
      C S Okereke, A M Kadry, M S Abdel-Rahman, R A Davis and M A Friedman
      Drug Metabolism and Disposition September 1993, 21 (5) 788-791;

  8. Fung, H L

    1. Nitrite ion is not an active intermediate in the vascular metabolism of organic nitrates and organic nitrites to nitric oxide.
      E A Kowaluk, S J Chung and H L Fung
      Drug Metabolism and Disposition September 1993, 21 (5) 967-969;

G

  1. Giachetti, A

    1. Pharmacokinetics and pharmacodynamics of idrapril in rats, dogs, and humans.
      M Criscuoli, A Lippi, G Mengozzi, G Sardelli, A Subissi and A Giachetti
      Drug Metabolism and Disposition September 1993, 21 (5) 835-840;

  2. Goel, O P

    1. Bioactivation and irreversible binding of the cognition activator tacrine using human and rat liver microsomal preparations. Species difference.
      T F Woolf, W F Pool, S M Bjorge, T Chang, O P Goel, C F Purchase, M C Schroeder, K L Kunze and W F Trager
      Drug Metabolism and Disposition September 1993, 21 (5) 874-882;

  3. Granneman, G R

    1. Differences in the stereoselective pharmacokinetics of pazinaclone (DN-2327), a new anxiolytic, and its active metabolite after intravenous and oral single doses to dogs.
      Z Hussein, D J Mulford, B A Bopp and G R Granneman
      Drug Metabolism and Disposition September 1993, 21 (5) 805-810;

  4. Griffin, R J

    1. Metabolism and elimination of oxazepam in B6C3F1 and Swiss-Webster mice.
      R J Griffin and L T Burka
      Drug Metabolism and Disposition September 1993, 21 (5) 918-926;

  5. Grossman, S J

    1. Characterization of verlukast metabolites arising from an epoxide intermediate produced with hepatic microsomes from beta-naphthoflavone-treated rodents (P-4501A1).
      D A Nicoll-Griffith, N Chauret, J A Yergey, L A Trimble, L Favreau, R Zamboni, S J Grossman, J Drey and E Herold
      Drug Metabolism and Disposition September 1993, 21 (5) 861-867;

H

  1. Hasinoff, B B

    1. Enzymatic ring-opening reactions of the chiral cardioprotective agent (+) (S)-ICRF-187 and its (-) (R)-enantiomer ICRF-186 by dihydropyrimidine amidohydrolase.
      B B Hasinoff
      Drug Metabolism and Disposition September 1993, 21 (5) 883-888;

  2. Heinrich, N

    1. Disposition of the 3H-labeled gonadotropin-releasing hormone analog buserelin in rats.
      H Berger, J Sandow, N Heinrich, E Albrecht, U Kertscher and J Oehlke
      Drug Metabolism and Disposition September 1993, 21 (5) 818-822;

  3. Herold, E

    1. Characterization of verlukast metabolites arising from an epoxide intermediate produced with hepatic microsomes from beta-naphthoflavone-treated rodents (P-4501A1).
      D A Nicoll-Griffith, N Chauret, J A Yergey, L A Trimble, L Favreau, R Zamboni, S J Grossman, J Drey and E Herold
      Drug Metabolism and Disposition September 1993, 21 (5) 861-867;

  4. Horecký, J

    1. NG-nitro-L-arginine pharmacokinetics in rats after a single intravascular and oral dose: an appearance of secondary concentration time peaks.
      V K Piotrovskij, Z Kállay, K Krejcy, J Horecký, T Trnovec and G Raberger
      Drug Metabolism and Disposition September 1993, 21 (5) 962-964;

  5. Huskey, S E

    1. N-glucuronidation reactions. I. Tetrazole N-glucuronidation of selected angiotensin II receptor antagonists in hepatic microsomes from rats, dogs, monkeys, and humans.
      S E Huskey, R R Miller and S H Chiu
      Drug Metabolism and Disposition September 1993, 21 (5) 792-799;

  6. Hussein, Z

    1. Differences in the stereoselective pharmacokinetics of pazinaclone (DN-2327), a new anxiolytic, and its active metabolite after intravenous and oral single doses to dogs.
      Z Hussein, D J Mulford, B A Bopp and G R Granneman
      Drug Metabolism and Disposition September 1993, 21 (5) 805-810;

  7. Hwang, I Y

    1. Targeting of 6-mercaptopurine to the kidneys. Metabolism and kidney-selectivity of S-(6-purinyl)-L-cysteine analogs in rats.
      A A Elfarra and I Y Hwang
      Drug Metabolism and Disposition September 1993, 21 (5) 841-845;

I

  1. Iyer, K R

    1. Glucuronidation as a transient intermediate metabolic step in the elimination of (-)-carbovir. Identification of (-)-carbovir-5'-O-glucuronide in rat bile.
      C L Zimmerman, K R Iyer, A L Faudskar and R P Remmel
      Drug Metabolism and Disposition September 1993, 21 (5) 902-910;

J

  1. Jayyosi, Z

    1. Identification of cytochrome P-450 isozymes involved in the hydroxylation of dantrolene by rat liver microsomes.
      Z Jayyosi, J Villoutreix, J M Ziegler, A M Batt, F De Maack, G Siest and P E Thomas
      Drug Metabolism and Disposition September 1993, 21 (5) 939-945;

K

  1. Kadry, A M

    1. Metabolism of benzophenone-3 in rats.
      C S Okereke, A M Kadry, M S Abdel-Rahman, R A Davis and M A Friedman
      Drug Metabolism and Disposition September 1993, 21 (5) 788-791;

  2. Kaiser, D G

    1. Disposition of tirilazad (U74006F), a 21-aminosteroid, in the plasma, heart, brain, and liver of the rat.
      S C Laizure, L K Franklin, D G Kaiser, C L Williams, R C Stevens, P L Sanders and M Miller
      Drug Metabolism and Disposition September 1993, 21 (5) 951-954;

  3. Kállay, Z

    1. NG-nitro-L-arginine pharmacokinetics in rats after a single intravascular and oral dose: an appearance of secondary concentration time peaks.
      V K Piotrovskij, Z Kállay, K Krejcy, J Horecký, T Trnovec and G Raberger
      Drug Metabolism and Disposition September 1993, 21 (5) 962-964;

  4. Keller, D A

    1. A strategy for characterization of polyethylene glycol-derivatized proteins. A mass spectrometric analysis of the attachment sites in polyethylene glycol-derivatized superoxide dismutase.
      M M Vestling, C M Murphy, D A Keller, C Fenselau, J Dedinas, D L Ladd and M A Olsen
      Drug Metabolism and Disposition September 1993, 21 (5) 911-917;

  5. Kertscher, U

    1. Disposition of the 3H-labeled gonadotropin-releasing hormone analog buserelin in rats.
      H Berger, J Sandow, N Heinrich, E Albrecht, U Kertscher and J Oehlke
      Drug Metabolism and Disposition September 1993, 21 (5) 818-822;

  6. Kitada, M

    1. Rat liver microsomal cytochrome P-450 responsible for reductive metabolism of zonisamide.
      H Nakasa, M Komiya, S Ohmori, T Rikihisa and M Kitada
      Drug Metabolism and Disposition September 1993, 21 (5) 777-781;

  7. Komiya, M

    1. Rat liver microsomal cytochrome P-450 responsible for reductive metabolism of zonisamide.
      H Nakasa, M Komiya, S Ohmori, T Rikihisa and M Kitada
      Drug Metabolism and Disposition September 1993, 21 (5) 777-781;

  8. Kowaluk, E A

    1. Nitrite ion is not an active intermediate in the vascular metabolism of organic nitrates and organic nitrites to nitric oxide.
      E A Kowaluk, S J Chung and H L Fung
      Drug Metabolism and Disposition September 1993, 21 (5) 967-969;

  9. Krejcy, K

    1. NG-nitro-L-arginine pharmacokinetics in rats after a single intravascular and oral dose: an appearance of secondary concentration time peaks.
      V K Piotrovskij, Z Kállay, K Krejcy, J Horecký, T Trnovec and G Raberger
      Drug Metabolism and Disposition September 1993, 21 (5) 962-964;

  10. Kunze, K L

    1. Bioactivation and irreversible binding of the cognition activator tacrine using human and rat liver microsomal preparations. Species difference.
      T F Woolf, W F Pool, S M Bjorge, T Chang, O P Goel, C F Purchase, M C Schroeder, K L Kunze and W F Trager
      Drug Metabolism and Disposition September 1993, 21 (5) 874-882;

  11. Kyerematen, G A

    1. Rates of excretion of cotinine, nicotine glucuronide, and 3-hydroxycotinine glucuronide in rat bile.
      M J Seaton, G A Kyerematen and E S Vesell
      Drug Metabolism and Disposition September 1993, 21 (5) 927-932;

L

  1. Lacarelle, B

    1. Effect of anticancer drugs on the glucuronidation of 3'-azido-3'-deoxythymidine in human liver microsomes.
      J F Rajaonarison, B Lacarelle, J Catalin, A Durand and J P Cano
      Drug Metabolism and Disposition September 1993, 21 (5) 823-829;

  2. Ladd, D L

    1. A strategy for characterization of polyethylene glycol-derivatized proteins. A mass spectrometric analysis of the attachment sites in polyethylene glycol-derivatized superoxide dismutase.
      M M Vestling, C M Murphy, D A Keller, C Fenselau, J Dedinas, D L Ladd and M A Olsen
      Drug Metabolism and Disposition September 1993, 21 (5) 911-917;

  3. Laizure, S C

    1. Disposition of tirilazad (U74006F), a 21-aminosteroid, in the plasma, heart, brain, and liver of the rat.
      S C Laizure, L K Franklin, D G Kaiser, C L Williams, R C Stevens, P L Sanders and M Miller
      Drug Metabolism and Disposition September 1993, 21 (5) 951-954;

  4. Lhoëst, G

    1. Isolation and identification of a novel isomerized epoxide metabolite of FK-506 from erythromycin-induced rabbit liver microsomes.
      G Lhoëst, N Maton and R K Verbeeck
      Drug Metabolism and Disposition September 1993, 21 (5) 850-854;

  5. Lin, J H

    1. Uptake of alendronate by bone tissue in hypocalcemic and hypercalcemic rats.
      J H Lin, I W Chen and F A Deluna
      Drug Metabolism and Disposition September 1993, 21 (5) 800-804;

  6. Lippi, A

    1. Pharmacokinetics and pharmacodynamics of idrapril in rats, dogs, and humans.
      M Criscuoli, A Lippi, G Mengozzi, G Sardelli, A Subissi and A Giachetti
      Drug Metabolism and Disposition September 1993, 21 (5) 835-840;

  7. Loiseau, P

    1. Model systems for oxidative drug metabolism studies. Catalytic behavior of water-soluble metalloporphyrins depends on both the intrinsic robustness of the catalyst and the nature of substrates.
      M Vidal, M Bonnafous, S Defrance, P Loiseau, J Bernadou and B Meunier
      Drug Metabolism and Disposition September 1993, 21 (5) 811-817;

M

  1. Martell, K J

    1. N-acetylation polymorphism in liver and pancreas of inbred rats.
      K J Martell and W W Weber
      Drug Metabolism and Disposition September 1993, 21 (5) 965-966;

  2. Maton, N

    1. Isolation and identification of a novel isomerized epoxide metabolite of FK-506 from erythromycin-induced rabbit liver microsomes.
      G Lhoëst, N Maton and R K Verbeeck
      Drug Metabolism and Disposition September 1993, 21 (5) 850-854;

  3. McClure, H M

    1. Pharmacokinetics and metabolism of 3'-azido-2',3'-dideoxy-5-methylcytidine in rhesus monkeys.
      F D Boudinot, R F Schinazi, K J Doshi, H M McClure and C K Chu
      Drug Metabolism and Disposition September 1993, 21 (5) 855-860;

  4. Mengozzi, G

    1. Pharmacokinetics and pharmacodynamics of idrapril in rats, dogs, and humans.
      M Criscuoli, A Lippi, G Mengozzi, G Sardelli, A Subissi and A Giachetti
      Drug Metabolism and Disposition September 1993, 21 (5) 835-840;

  5. Meunier, B

    1. Model systems for oxidative drug metabolism studies. Catalytic behavior of water-soluble metalloporphyrins depends on both the intrinsic robustness of the catalyst and the nature of substrates.
      M Vidal, M Bonnafous, S Defrance, P Loiseau, J Bernadou and B Meunier
      Drug Metabolism and Disposition September 1993, 21 (5) 811-817;

  6. Miller, M

    1. Disposition of tirilazad (U74006F), a 21-aminosteroid, in the plasma, heart, brain, and liver of the rat.
      S C Laizure, L K Franklin, D G Kaiser, C L Williams, R C Stevens, P L Sanders and M Miller
      Drug Metabolism and Disposition September 1993, 21 (5) 951-954;

  7. Miller, R R

    1. N-glucuronidation reactions. I. Tetrazole N-glucuronidation of selected angiotensin II receptor antagonists in hepatic microsomes from rats, dogs, monkeys, and humans.
      S E Huskey, R R Miller and S H Chiu
      Drug Metabolism and Disposition September 1993, 21 (5) 792-799;

  8. Moussa, M

    1. Temporal effects of 1,1-dichloroethylene on nonprotein sulfhydryl content in murine lung and liver.
      P G Forkert and M Moussa
      Drug Metabolism and Disposition September 1993, 21 (5) 770-776;

  9. Mulford, D J

    1. Differences in the stereoselective pharmacokinetics of pazinaclone (DN-2327), a new anxiolytic, and its active metabolite after intravenous and oral single doses to dogs.
      Z Hussein, D J Mulford, B A Bopp and G R Granneman
      Drug Metabolism and Disposition September 1993, 21 (5) 805-810;

  10. Murphy, C M

    1. A strategy for characterization of polyethylene glycol-derivatized proteins. A mass spectrometric analysis of the attachment sites in polyethylene glycol-derivatized superoxide dismutase.
      M M Vestling, C M Murphy, D A Keller, C Fenselau, J Dedinas, D L Ladd and M A Olsen
      Drug Metabolism and Disposition September 1993, 21 (5) 911-917;

N

  1. Nakasa, H

    1. Rat liver microsomal cytochrome P-450 responsible for reductive metabolism of zonisamide.
      H Nakasa, M Komiya, S Ohmori, T Rikihisa and M Kitada
      Drug Metabolism and Disposition September 1993, 21 (5) 777-781;

  2. Nicoll-Griffith, D A

    1. Characterization of verlukast metabolites arising from an epoxide intermediate produced with hepatic microsomes from beta-naphthoflavone-treated rodents (P-4501A1).
      D A Nicoll-Griffith, N Chauret, J A Yergey, L A Trimble, L Favreau, R Zamboni, S J Grossman, J Drey and E Herold
      Drug Metabolism and Disposition September 1993, 21 (5) 861-867;

O

  1. Oehlke, J

    1. Disposition of the 3H-labeled gonadotropin-releasing hormone analog buserelin in rats.
      H Berger, J Sandow, N Heinrich, E Albrecht, U Kertscher and J Oehlke
      Drug Metabolism and Disposition September 1993, 21 (5) 818-822;

  2. Ohmori, S

    1. Rat liver microsomal cytochrome P-450 responsible for reductive metabolism of zonisamide.
      H Nakasa, M Komiya, S Ohmori, T Rikihisa and M Kitada
      Drug Metabolism and Disposition September 1993, 21 (5) 777-781;

  3. Okereke, C S

    1. Metabolism of benzophenone-3 in rats.
      C S Okereke, A M Kadry, M S Abdel-Rahman, R A Davis and M A Friedman
      Drug Metabolism and Disposition September 1993, 21 (5) 788-791;

  4. Olsen, M A

    1. A strategy for characterization of polyethylene glycol-derivatized proteins. A mass spectrometric analysis of the attachment sites in polyethylene glycol-derivatized superoxide dismutase.
      M M Vestling, C M Murphy, D A Keller, C Fenselau, J Dedinas, D L Ladd and M A Olsen
      Drug Metabolism and Disposition September 1993, 21 (5) 911-917;

  5. Oxford, J

    1. Disposition of sumatriptan in laboratory animals and humans.
      C M Dixon, D A Saynor, P D Andrew, J Oxford, A Bradbury and M H Tarbit
      Drug Metabolism and Disposition September 1993, 21 (5) 761-769;

P

  1. Piotrovskij, V K

    1. NG-nitro-L-arginine pharmacokinetics in rats after a single intravascular and oral dose: an appearance of secondary concentration time peaks.
      V K Piotrovskij, Z Kállay, K Krejcy, J Horecký, T Trnovec and G Raberger
      Drug Metabolism and Disposition September 1993, 21 (5) 962-964;

  2. Pool, W F

    1. Bioactivation and irreversible binding of the cognition activator tacrine using human and rat liver microsomal preparations. Species difference.
      T F Woolf, W F Pool, S M Bjorge, T Chang, O P Goel, C F Purchase, M C Schroeder, K L Kunze and W F Trager
      Drug Metabolism and Disposition September 1993, 21 (5) 874-882;

  3. Purchase, C F

    1. Bioactivation and irreversible binding of the cognition activator tacrine using human and rat liver microsomal preparations. Species difference.
      T F Woolf, W F Pool, S M Bjorge, T Chang, O P Goel, C F Purchase, M C Schroeder, K L Kunze and W F Trager
      Drug Metabolism and Disposition September 1993, 21 (5) 874-882;

R

  1. Raberger, G

    1. NG-nitro-L-arginine pharmacokinetics in rats after a single intravascular and oral dose: an appearance of secondary concentration time peaks.
      V K Piotrovskij, Z Kállay, K Krejcy, J Horecký, T Trnovec and G Raberger
      Drug Metabolism and Disposition September 1993, 21 (5) 962-964;

  2. Rajaonarison, J F

    1. Effect of anticancer drugs on the glucuronidation of 3'-azido-3'-deoxythymidine in human liver microsomes.
      J F Rajaonarison, B Lacarelle, J Catalin, A Durand and J P Cano
      Drug Metabolism and Disposition September 1993, 21 (5) 823-829;

  3. Remmel, R P

    1. Glucuronidation as a transient intermediate metabolic step in the elimination of (-)-carbovir. Identification of (-)-carbovir-5'-O-glucuronide in rat bile.
      C L Zimmerman, K R Iyer, A L Faudskar and R P Remmel
      Drug Metabolism and Disposition September 1993, 21 (5) 902-910;

  4. Renner, U

    1. Detection and identification of human urinary metabolites of biantrazole (CI-941).
      J Blanz, U Renner, K Schmeer, G Ehninger and K P Zeller
      Drug Metabolism and Disposition September 1993, 21 (5) 955-961;

  5. Rikihisa, T

    1. Rat liver microsomal cytochrome P-450 responsible for reductive metabolism of zonisamide.
      H Nakasa, M Komiya, S Ohmori, T Rikihisa and M Kitada
      Drug Metabolism and Disposition September 1993, 21 (5) 777-781;

  6. Robertson, L W

    1. Effect of nutritional obesity on the induction of CYP2B enzymes following phenobarbital treatment.
      P N Zannikos, A M Bandyopadhyay, L W Robertson and R A Blouin
      Drug Metabolism and Disposition September 1993, 21 (5) 782-787;

  7. Rosenberg, D W

    1. Pharmacokinetics of cobalt chloride and cobalt-protoporphyrin.
      D W Rosenberg
      Drug Metabolism and Disposition September 1993, 21 (5) 846-849;

  8. Rowland, M

    1. Relationship between lipophilicity and hepatic dispersion and distribution for a homologous series of barbiturates in the isolated perfused in situ rat liver.
      C H Chou, A M Evans, G Fornasini and M Rowland
      Drug Metabolism and Disposition September 1993, 21 (5) 933-938;

S

  1. Sanders, P L

    1. Disposition of tirilazad (U74006F), a 21-aminosteroid, in the plasma, heart, brain, and liver of the rat.
      S C Laizure, L K Franklin, D G Kaiser, C L Williams, R C Stevens, P L Sanders and M Miller
      Drug Metabolism and Disposition September 1993, 21 (5) 951-954;

  2. Sandow, J

    1. Disposition of the 3H-labeled gonadotropin-releasing hormone analog buserelin in rats.
      H Berger, J Sandow, N Heinrich, E Albrecht, U Kertscher and J Oehlke
      Drug Metabolism and Disposition September 1993, 21 (5) 818-822;

  3. Sardelli, G

    1. Pharmacokinetics and pharmacodynamics of idrapril in rats, dogs, and humans.
      M Criscuoli, A Lippi, G Mengozzi, G Sardelli, A Subissi and A Giachetti
      Drug Metabolism and Disposition September 1993, 21 (5) 835-840;

  4. Saynor, D A

    1. Disposition of sumatriptan in laboratory animals and humans.
      C M Dixon, D A Saynor, P D Andrew, J Oxford, A Bradbury and M H Tarbit
      Drug Metabolism and Disposition September 1993, 21 (5) 761-769;

  5. Schinazi, R F

    1. Pharmacokinetics and metabolism of 3'-azido-2',3'-dideoxy-5-methylcytidine in rhesus monkeys.
      F D Boudinot, R F Schinazi, K J Doshi, H M McClure and C K Chu
      Drug Metabolism and Disposition September 1993, 21 (5) 855-860;

  6. Schmeer, K

    1. Detection and identification of human urinary metabolites of biantrazole (CI-941).
      J Blanz, U Renner, K Schmeer, G Ehninger and K P Zeller
      Drug Metabolism and Disposition September 1993, 21 (5) 955-961;

  7. Schroeder, M C

    1. Bioactivation and irreversible binding of the cognition activator tacrine using human and rat liver microsomal preparations. Species difference.
      T F Woolf, W F Pool, S M Bjorge, T Chang, O P Goel, C F Purchase, M C Schroeder, K L Kunze and W F Trager
      Drug Metabolism and Disposition September 1993, 21 (5) 874-882;

  8. Seaton, M J

    1. Rates of excretion of cotinine, nicotine glucuronide, and 3-hydroxycotinine glucuronide in rat bile.
      M J Seaton, G A Kyerematen and E S Vesell
      Drug Metabolism and Disposition September 1993, 21 (5) 927-932;

  9. Shear, N H

    1. N-chlorination of sulfamethoxazole and dapsone by the myeloperoxidase system.
      J P Uetrecht, N H Shear and N Zahid
      Drug Metabolism and Disposition September 1993, 21 (5) 830-834;

  10. Shipley, L A

    1. Comparison of human and rhesus monkey in vitro phase I and phase II hepatic drug metabolism activities.
      J C Stevens, L A Shipley, J R Cashman, M Vandenbranden and S A Wrighton
      Drug Metabolism and Disposition September 1993, 21 (5) 753-760;

  11. Siest, G

    1. Identification of cytochrome P-450 isozymes involved in the hydroxylation of dantrolene by rat liver microsomes.
      Z Jayyosi, J Villoutreix, J M Ziegler, A M Batt, F De Maack, G Siest and P E Thomas
      Drug Metabolism and Disposition September 1993, 21 (5) 939-945;

  12. Sommadossi, J P

    1. Reduction of 3'-azido-2',3'-dideoxynucleosides to their 3'-amino metabolite is mediated by cytochrome P-450 and NADPH-cytochrome P-450 reductase in rat liver microsomes.
      E M Cretton and J P Sommadossi
      Drug Metabolism and Disposition September 1993, 21 (5) 946-950;

  13. Song, H

    1. Drug metabolism studies using "intrinsic" and "extrinsic" labels. A demonstration using 15N vs. Cl in midazolam.
      H Song and F Abramson
      Drug Metabolism and Disposition September 1993, 21 (5) 868-873;

  14. Stevens, J C

    1. Comparison of human and rhesus monkey in vitro phase I and phase II hepatic drug metabolism activities.
      J C Stevens, L A Shipley, J R Cashman, M Vandenbranden and S A Wrighton
      Drug Metabolism and Disposition September 1993, 21 (5) 753-760;

  15. Stevens, R C

    1. Disposition of tirilazad (U74006F), a 21-aminosteroid, in the plasma, heart, brain, and liver of the rat.
      S C Laizure, L K Franklin, D G Kaiser, C L Williams, R C Stevens, P L Sanders and M Miller
      Drug Metabolism and Disposition September 1993, 21 (5) 951-954;

  16. Subissi, A

    1. Pharmacokinetics and pharmacodynamics of idrapril in rats, dogs, and humans.
      M Criscuoli, A Lippi, G Mengozzi, G Sardelli, A Subissi and A Giachetti
      Drug Metabolism and Disposition September 1993, 21 (5) 835-840;

T

  1. Tarbit, M H

    1. Disposition of sumatriptan in laboratory animals and humans.
      C M Dixon, D A Saynor, P D Andrew, J Oxford, A Bradbury and M H Tarbit
      Drug Metabolism and Disposition September 1993, 21 (5) 761-769;

  2. Thomas, P E

    1. Identification of cytochrome P-450 isozymes involved in the hydroxylation of dantrolene by rat liver microsomes.
      Z Jayyosi, J Villoutreix, J M Ziegler, A M Batt, F De Maack, G Siest and P E Thomas
      Drug Metabolism and Disposition September 1993, 21 (5) 939-945;

  3. Trager, W F

    1. Bioactivation and irreversible binding of the cognition activator tacrine using human and rat liver microsomal preparations. Species difference.
      T F Woolf, W F Pool, S M Bjorge, T Chang, O P Goel, C F Purchase, M C Schroeder, K L Kunze and W F Trager
      Drug Metabolism and Disposition September 1993, 21 (5) 874-882;

  4. Trimble, L A

    1. Characterization of verlukast metabolites arising from an epoxide intermediate produced with hepatic microsomes from beta-naphthoflavone-treated rodents (P-4501A1).
      D A Nicoll-Griffith, N Chauret, J A Yergey, L A Trimble, L Favreau, R Zamboni, S J Grossman, J Drey and E Herold
      Drug Metabolism and Disposition September 1993, 21 (5) 861-867;

  5. Trnovec, T

    1. NG-nitro-L-arginine pharmacokinetics in rats after a single intravascular and oral dose: an appearance of secondary concentration time peaks.
      V K Piotrovskij, Z Kállay, K Krejcy, J Horecký, T Trnovec and G Raberger
      Drug Metabolism and Disposition September 1993, 21 (5) 962-964;

U

  1. Uetrecht, J P

    1. N-chlorination of sulfamethoxazole and dapsone by the myeloperoxidase system.
      J P Uetrecht, N H Shear and N Zahid
      Drug Metabolism and Disposition September 1993, 21 (5) 830-834;

V

  1. Vandenbranden, M

    1. Comparison of human and rhesus monkey in vitro phase I and phase II hepatic drug metabolism activities.
      J C Stevens, L A Shipley, J R Cashman, M Vandenbranden and S A Wrighton
      Drug Metabolism and Disposition September 1993, 21 (5) 753-760;

  2. Verbeeck, R K

    1. Isolation and identification of a novel isomerized epoxide metabolite of FK-506 from erythromycin-induced rabbit liver microsomes.
      G Lhoëst, N Maton and R K Verbeeck
      Drug Metabolism and Disposition September 1993, 21 (5) 850-854;

  3. Vesell, E S

    1. Rates of excretion of cotinine, nicotine glucuronide, and 3-hydroxycotinine glucuronide in rat bile.
      M J Seaton, G A Kyerematen and E S Vesell
      Drug Metabolism and Disposition September 1993, 21 (5) 927-932;

  4. Vestling, M M

    1. A strategy for characterization of polyethylene glycol-derivatized proteins. A mass spectrometric analysis of the attachment sites in polyethylene glycol-derivatized superoxide dismutase.
      M M Vestling, C M Murphy, D A Keller, C Fenselau, J Dedinas, D L Ladd and M A Olsen
      Drug Metabolism and Disposition September 1993, 21 (5) 911-917;

  5. Vidal, M

    1. Model systems for oxidative drug metabolism studies. Catalytic behavior of water-soluble metalloporphyrins depends on both the intrinsic robustness of the catalyst and the nature of substrates.
      M Vidal, M Bonnafous, S Defrance, P Loiseau, J Bernadou and B Meunier
      Drug Metabolism and Disposition September 1993, 21 (5) 811-817;

  6. Villoutreix, J

    1. Identification of cytochrome P-450 isozymes involved in the hydroxylation of dantrolene by rat liver microsomes.
      Z Jayyosi, J Villoutreix, J M Ziegler, A M Batt, F De Maack, G Siest and P E Thomas
      Drug Metabolism and Disposition September 1993, 21 (5) 939-945;

W

  1. Weber, W W

    1. N-acetylation polymorphism in liver and pancreas of inbred rats.
      K J Martell and W W Weber
      Drug Metabolism and Disposition September 1993, 21 (5) 965-966;

  2. Williams, C L

    1. Disposition of tirilazad (U74006F), a 21-aminosteroid, in the plasma, heart, brain, and liver of the rat.
      S C Laizure, L K Franklin, D G Kaiser, C L Williams, R C Stevens, P L Sanders and M Miller
      Drug Metabolism and Disposition September 1993, 21 (5) 951-954;

  3. Woolf, T F

    1. Bioactivation and irreversible binding of the cognition activator tacrine using human and rat liver microsomal preparations. Species difference.
      T F Woolf, W F Pool, S M Bjorge, T Chang, O P Goel, C F Purchase, M C Schroeder, K L Kunze and W F Trager
      Drug Metabolism and Disposition September 1993, 21 (5) 874-882;

  4. Wrighton, S A

    1. Comparison of human and rhesus monkey in vitro phase I and phase II hepatic drug metabolism activities.
      J C Stevens, L A Shipley, J R Cashman, M Vandenbranden and S A Wrighton
      Drug Metabolism and Disposition September 1993, 21 (5) 753-760;

Y

  1. Yergey, J A

    1. Characterization of verlukast metabolites arising from an epoxide intermediate produced with hepatic microsomes from beta-naphthoflavone-treated rodents (P-4501A1).
      D A Nicoll-Griffith, N Chauret, J A Yergey, L A Trimble, L Favreau, R Zamboni, S J Grossman, J Drey and E Herold
      Drug Metabolism and Disposition September 1993, 21 (5) 861-867;

Z

  1. Zahid, N

    1. N-chlorination of sulfamethoxazole and dapsone by the myeloperoxidase system.
      J P Uetrecht, N H Shear and N Zahid
      Drug Metabolism and Disposition September 1993, 21 (5) 830-834;

  2. Zamboni, R

    1. Characterization of verlukast metabolites arising from an epoxide intermediate produced with hepatic microsomes from beta-naphthoflavone-treated rodents (P-4501A1).
      D A Nicoll-Griffith, N Chauret, J A Yergey, L A Trimble, L Favreau, R Zamboni, S J Grossman, J Drey and E Herold
      Drug Metabolism and Disposition September 1993, 21 (5) 861-867;

  3. Zannikos, P N

    1. Effect of nutritional obesity on the induction of CYP2B enzymes following phenobarbital treatment.
      P N Zannikos, A M Bandyopadhyay, L W Robertson and R A Blouin
      Drug Metabolism and Disposition September 1993, 21 (5) 782-787;

  4. Zeller, K P

    1. Detection and identification of human urinary metabolites of biantrazole (CI-941).
      J Blanz, U Renner, K Schmeer, G Ehninger and K P Zeller
      Drug Metabolism and Disposition September 1993, 21 (5) 955-961;

  5. Ziegler, J M

    1. Identification of cytochrome P-450 isozymes involved in the hydroxylation of dantrolene by rat liver microsomes.
      Z Jayyosi, J Villoutreix, J M Ziegler, A M Batt, F De Maack, G Siest and P E Thomas
      Drug Metabolism and Disposition September 1993, 21 (5) 939-945;

  6. Zimmerman, C L

    1. Glucuronidation as a transient intermediate metabolic step in the elimination of (-)-carbovir. Identification of (-)-carbovir-5'-O-glucuronide in rat bile.
      C L Zimmerman, K R Iyer, A L Faudskar and R P Remmel
      Drug Metabolism and Disposition September 1993, 21 (5) 902-910;
Back to top

In this issue